O
1.70
-0.04 (-2.30%)
| Penutupan Terdahulu | 1.74 |
| Buka | 1.74 |
| Jumlah Dagangan | 2,933,769 |
| Purata Dagangan (3B) | 4,745,491 |
| Modal Pasaran | 1,141,635,072 |
| Harga / Jualan (P/S) | 1.45 |
| Harga / Buku (P/B) | 0.870 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Keuntungan | -7.46% |
| Margin Operasi (TTM) | -18.05% |
| EPS Cair (TTM) | -0.080 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 36.94% |
| Nisbah Semasa (MRQ) | 3.43 |
| Aliran Tunai Operasi (OCF TTM) | -183.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -129.55 M |
| Pulangan Atas Aset (ROA TTM) | -8.12% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | Opko Health, Inc. | Menaik | Bercampur |
AISkor Stockmoo
1.1
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 2.5 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.10 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 55.26% |
| % Dimiliki oleh Institusi | 29.89% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 3.00 (HC Wainwright & Co., 76.47%) | Beli |
| Median | 2.63 (54.71%) | |
| Rendah | 2.25 (Barrington Research, 32.35%) | Beli |
| Purata | 2.63 (54.71%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.66 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Apr 2025 | 3.00 (76.47%) | Beli | 1.53 |
| 19 Mar 2025 | 3.00 (76.47%) | Beli | 1.86 | |
| Barrington Research | 12 Mar 2025 | 2.25 (32.35%) | Beli | 1.78 |
| 28 Feb 2025 | 2.25 (32.35%) | Beli | 1.74 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FROST PHILLIP MD ET AL | 1.66 | - | 100,000 | 166,000 |
| Jumlah Keseluruhan Kuantiti Bersih | 100,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 166,000 | |||
| Purata Pembelian Keseluruhan ($) | 1.66 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Pegawai | 01 Apr 2025 | Beli (+) | 100,000 | 1.66 | 166,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Apr 2025 | Pengumuman | NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program |
| 04 Apr 2025 | Pengumuman | OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program |
| 17 Mar 2025 | Pengumuman | OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders |
| 11 Mar 2025 | Pengumuman | Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses |
| 27 Feb 2025 | Pengumuman | OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results |
| 13 Feb 2025 | Pengumuman | OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |